Introduction
Cytokines are known to play important roles in the growth and differentiation of hematopoietic cells. In particular, cytokines, the most well studied of which is IL-6, play important roles in Bcell growth and differentiation into plasma cells and are essential growth and survival factors for neoplastic cells in the pathogenesis of multiple myeloma (MM) [1] [2] [3] . Like other cytokines, IL-6 binds to a specific membrane receptor (IL-6R), and the IL-6/IL6R complex induces the dimerization of the receptor subunit gp130. After receptor binding, members of the Janus kinase (Jak) family become activated, which in turn cross-phosphorylate both each other and the cytoplasmic domains of the receptors on tyrosine residues. This provides docking sites for latent transcription factors called signal transducers and activators of transcription (STATs). These transcription factors become phosphorylated after docking and dimerize before entering the nucleus and initiating transcription of target genes 4, 5 .
Recently, a family of proteins functioning as negative regulators of Jak/STAT signaling has been identified, revealing one mechanism for the regulation of cytokine signal transduction.
Proteins belonging to this family are termed suppressors of cytokine signaling (SOCS) and are characterized by the presence of a src homology (SH2) domain and a carboxyl-terminal conserved domain called the SOCS box. Eight members of the SOCS family have been identified so far, termed SOCS-1 to SOCS-7 and CIS (cytokine-inducible SH2-containing protein) [4] [5] [6] [7] .
SOCS-1 was discovered in 1997 by three independent experimental approaches. In one study an expression library was used to identify molecules capable of blocking IL-6-mediated differentiation of murine M1 cells 8 ; the second group used a yeast-two-hybrid screen to detect proteins able to interact with Jak2 9 ; and the third approach used a screen with antibodies to find proteins with homology with the SH2 domain of STATs 10 . The SOCS-1 protein has been shown For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 4 to interact directly with active Jaks by binding to their activation loop in a phosphorylationdependent manner. The blocking of Jak activation results in inhibition of the Jak/STAT signal transduction pathway. SOCS-1 suppresses signaling by a wide variety of cytokines including IL-6, IL-4, leukemia inhibitory factor, oncostatin M, growth hormone, prolactin, thrombopoietin and interferons 11 . It has been shown that regulation of cytokine signaling by SOCS-1 is important in normal lymphocyte development and differentiation 12, 13 .
The first report demonstrating involvement of SOCS-1 in carcinogenesis revealed that SOCS-1 is frequently silenced by hypermethylation in hepatocellular carcinoma (HCC) 14 .
Restoration of SOCS-1 in HCC cell lines by transient transfection resulted in growth suppression and induction of apoptosis 14 . The silencing of gene transcription associated with aberrant DNA methylation of CpG dinucleotides in normally unmethylated gene promoter regions is the most widely studied epigenetic abnormality in tumorigenesis. 
Material and methods

MM patient and control samples
After informed consent was given, bone marrow (BM) specimens were aspirated during routine clinical assessment of 35 MM patients (28 at diagnosis, 7 at relapse; 22 males, 13 females), who presented at the University Hospital Aachen, Germany between 1995 and 2000. MM diagnosis and staging classification were made in accordance with standard criteria 23 
Sodium bisulfite treatment and methylation-specific polymerase chain reaction (MSP)
Genomic DNA was isolated from cell lines and primary tissues by standard methods. The methylation status of SOCS-1 was analyzed using the MSP technique 25 . This assay distinguishes unmethylated form methylated alleles in a given gene on the basis of sequence changes induced by sodium bisulfite treatment of DNA, which converts all unmethylated, but not methylated cytosines to uracil. Subsequently, the DNA region of interest is amplified with primer pairs specific for methylated versus unmethylated DNA. For SOCS-1 MSP analysis, approximately 1 µg of DNA was sodium bisulfite-modified and amplified using primers that were described previously 14 . Normal DNA from PB was treated in vitro with SssI methyltransferase (New England Biolabs) in order to generate a positive control for methylated alleles of SOCS-1 26 .
RNA isolation and reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was isolated using a commercially available kit (Qiagen) according to the 
Western blot analysis
Cell lysis and Western blot analysis for STAT3 phosphorylation were performed as described previously 14 . In brief, 60 µg total protein per sample were separated by SDS-PAGE and western blotted. For detection of phosphorylation of STAT3 we used anti-phospho-STAT3 antibody (New England Biolabs) according to the manufacturer's recommendations. After antibody removal, the blot was analyzed with anti-STAT-3 antibody (Santa Cruz Biotechnology).
Results
SOCS-1 methylation status in hematopoietic cell lines and normal tissues
We first analyzed the SOCS-1 methylation status by MSP in various human hematopoietic cell lines (Figure 1) . SOCS-1 hypermethylation was found in both IL-6-dependent MM cell lines 
SOCS-1 expression in MM cell lines
We next examined SOCS-1 expression in both MM cell lines by semi-quantitative RT-PCR (Figure 2 ). XG1 cells require the addition of exogenous IL-6 27 , while U266 cells depend on an IL-6 autocrine loop 28 . Despite the presence of IL-6 in the cell culture medium, the MM cell lines showed low (U266) or undetectable (XG1) SOCS-1 transcript levels ( Figure 2 ). For comparison, normal PBMNC incubated in IMDM with 20 % FCS and 10 U/ml IL-6 for 2 h showed strong 
SOCS-1 expression. Unstimulated PBMNC expressed SOCS-1 only a low levels (data not
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STAT3 phosphorylation
Having demonstrated that AG490 is capable of inducing apoptosis in the MM cell lines U266 and XG1, we then analyzed the impact of AG490 on the phosphorylation status of STAT3, which represents a downstream event in the Jak/STAT pathway. Figure 4 shows that AG490 was able to inhibit STAT3 phosphorylation in U266 cells, while there were only minor effects in XG1 cells. , and DAP-kinase in MM patients and cell lines 21, [31] [32] [33] [34] , demonstrating that epigenetic silencing of genes that effect cell cycle regulation and apoptosis pathways is an additional mechanism of gene inactivation in MM. In addition to its physiological role in antagonizing cytokine signaling, ectopic expression of SOCS-1 was shown to be capable of blocking the transforming activity of oncogenic forms of Jak2, kit, and abl 35, 36 . Furthermore, the TEL-Jak2 and v-abl-mediated phosphorylation of STAT proteins was inhibited by SOCS-1 overexpression 36 Our findings reveal an important novel epigenetic event in the pathogenesis of MM.
Silencing of SOCS-1 may result in increased responsiveness of the neoplastic clone to IL-6 signaling, thus supporting survival and expansion of MM cells. These findings provide not only new insights in the pathogenesis of MM but also support novel approaches in MM therapy, since hypermethylation-associated gene silencing is a potentially reversible phenomenon 37 .
Demethylating agents such as DAC have been shown to exert clinical efficacy in patients with AML and myelodysplastic syndrome 38, 39 . The high prevalence of SOCS-1 hypermethylation in MM indicates that this pathway may be a potential target for therapeutic intervention. While reactivation of genes like p15 INK4B and p16 INK4A could contribute to reconstitution of disrupted cell cycle regulation, reactivation of SOCS-1 might functionally restore the endogenous negative feedback loop of cytokine signaling. Since IL-6 has been shown to contribute to MM resistance to conventional therapy options such as corticosteroids 40 , inhibition of IL-6 signaling and other cytokines by SOCS-1 reactivation could potentially overcome such resistance. The combination of demethylating agents with conventional therapeutics or tyrosine kinase inhibitors might be a promising new strategy in MM therapy.
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